Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia

详细信息    查看全文

• 作者：Limin Liu (1) (2)
  Yanming Zhang (2)
  Zhengming Jin (1)
  Xingxia Zhang (2)
  Guangsheng Zhao (2)
  Yejun Si (2)
  Guoqiang Lin (2)
  Aidi Ma (2)
  Yingxin Sun (2)
  Li Wang (2)
  Depei Wu (1)
  
• 关键词：Acute myeloid leukemia ; Cytarabine ; Aclarubicin ; Granulocyte colony ; stimulating factor (G ; CSF)
• 刊名：International Journal of Hematology
• 出版年：2014
• 出版时间：May 2014
• 年：2014
• 卷：99
• 期：5
• 页码：603-608
• 全文大小：
• 参考文献：1. Freireich EJ. Four decades of therapy for AML. Leukemia. 1998;12(Suppl 1):S54-.
  2. Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010;3:17. CrossRef
  3. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60?years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-0. CrossRef
  4. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-6. CrossRef
  5. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249-9. CrossRef
  6. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010;3:8. CrossRef
  7. Jiang S, Ma X, Huang Y, Xu Y, Zheng R, Chiao JW. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol. 2010;3:48. CrossRef
  8. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, et al. Phase 1-a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009;2:20. CrossRef
  9. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10-.
  10. Wang Y, Li W, Chen S, Sun A, Wu D. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Leuk Res. 2011;35:604-. CrossRef
  11. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46-8. CrossRef
  12. Xue SL, Wu DP, Sun AN, Tang XW. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol. 2008;83:167-0. CrossRef
  13. He GS, Zhang X, Wu DP, Sun AN, Jin ZM, Qiu HY, et al. Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. Chin Med Sci J. 2009;24:178-1. CrossRef
  14. Hajji N, Mateos S, Pastor N, Dominguez I, Cortes F. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005;583:26-5. CrossRef
  15. Warrell RP Jr. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers. Drugs Exp Clin Res. 1986;12:275-2.
  16. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-29. CrossRef
  17. Lehne G, De Angelis P, Clausen OP, Rugstad HE. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer. 1996;74:1719-9. CrossRef
  18. Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71:238-4.
  19. Qian SX, Li JY, Tian T, Shen YF, Jiang YQ, Lu H, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res. 2007;31:1383-. CrossRef
  20. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Reviewed recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-. CrossRef
  21. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-3.
  22. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;67:1025-9. CrossRef
  23. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol. 2004;83:498-03. CrossRef
  24. Zhang L, Fan J, Ma CY, Wang X. The detection of G-CSFR and GM-CSFR expression and its significance in acute leukemia. J Clin Hematol. 2007;20:8-0.
  25. Bai A, Kojima H, Hori M, Nara N, Komeno T, Haseqawa Y, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol. 1999;27:259-5. CrossRef
  26. Katagiri T, Miyazawa K, Nishimaki J, Yaguchi M, Kawanishi Y, Ohyashiki K. Combination of granulocyte colony stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. Leuk Lymphoma. 2000;39:173-4. CrossRef
  
• 作者单位：Limin Liu (1) (2)
  Yanming Zhang (2)
  Zhengming Jin (1)
  Xingxia Zhang (2)
  Guangsheng Zhao (2)
  Yejun Si (2)
  Guoqiang Lin (2)
  Aidi Ma (2)
  Yingxin Sun (2)
  Li Wang (2)
  Depei Wu (1)
  
  1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 188 Shizi Street, Suzhou, 215006, Jiangsu, People’s Republic of China
  2. Department of Hematology, The Second People’s Hospital of Huai’an, 62 Huaihai South Street, Huai’an, 223002, People’s Republic of China
  
• ISSN：1865-3774

文摘

It is difficult for relapsed and refractory acute myeloid leukemia (AML) patients to achieve complete remission (CR). The CAG regimen [low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF)] has been used to treat relapsed and refractory AML patients, and showed good therapeutic efficacy. It is unknown, however, whether increasing the dose of aclarubicin in CAG regimen could treat relapsed or refractory AML safely and effectively. We evaluate the efficacy and tolerability of increasing the dose of aclarubicin in CAG regimen, in 37 relapsed or refractory AML patients. All patients were treated with CAG regimen including low-dose cytarabine (10?mg/m2 every 12?h, days 1-4), aclarubicin (5-?mg/m2 every day, days 1-4), and G-CSF (200?μg/m2 every day, days 1-4) priming. After a single course of therapy, the overall response [CR?+?partial remission (PR)] rate of all patients was 78.4?% (29/37), in which the CR rate was 62.2?% (23/37). There was no early death. The median overall survival was 6?months (range 2-6?months). Myelosuppression was ubiquitous, but tolerated. No severe non-hematologic toxicity was observed. Thus, increasing the dose of aclarubicin in CAG regimen can be used safely and effectively in the treatment of relapsed or refractory AML.